Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43240
UPID:
KLK10_HUMAN
Alternative names:
Normal epithelial cell-specific 1; Protease serine-like 1
Alternative UPACC:
O43240; A6NC12; Q53YL3; Q99920; Q9GZW9
Background:
Kallikrein-10, also known as Normal epithelial cell-specific 1 and Protease serine-like 1, plays a pivotal role in the regulation of cellular processes. Its tumor-suppressor function in breast and prostate cancer highlights its significance in cellular homeostasis and disease prevention.
Therapeutic significance:
Understanding the role of Kallikrein-10 could open doors to potential therapeutic strategies. Its involvement in critical cancer pathways offers a promising avenue for the development of targeted cancer therapies, especially for breast and prostate cancer.